Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Open Access
- 9 October 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 38 (6) , 1624-1633
- https://doi.org/10.1093/ije/dyp306
Abstract
Background Mortality in HIV-infected patients has declined substantially with combination antiretroviral therapy (ART), but it is unclear whether it has reached that of the general population. We compared mortality in patients starting ART in nine countries of Europe and North America with the corresponding general population, taking into account their response to ART. Methods Eligible patients were enrolled in prospective cohort studies participating in the ART Cohort Collaboration. We calculated the ratio of observed to expected deaths from all causes [standardized mortality ratio (SMR)], measuring time from 6 months after starting ART, according to risk group, clinical stage at the start of ART and CD4 cell count and viral load at 6 months. Expected numbers of deaths were obtained from age-, sex- and country-specific mortality rates. Results Among 29 935 eligible patients, 1134 deaths were recorded in 131 510 person-years of follow-up. The median age was 37 years, 8162 (27%) patients were females, 4400 (15%) were injecting drug users (IDUs) and 6738 (23%) had AIDS when starting ART. At 6 months, 23 539 patients (79%) had viral load measurements ≤500 copies/ml. The lowest SMR, 1.05 [95% confidence interval (CI) 0.82–1.35] was found for men who have sex with men (MSM) who started ART free of AIDS, reached a CD4 cell count of ≥350 cells/μL and suppressed viral replication to ≤500 copies/ml by the sixth month. In contrast, the SMR was 73.7 (95% CI 46.4–116.9) in IDUs who failed to suppress viral replication and had CD4 cell counts Conclusions In industrialized countries, the mortality experience of HIV-infected patients who start ART and survive the first 6 months continues to be higher than in the general population, but for many patients excess mortality is moderate and comparable with patients having other chronic conditions. Much of the excess mortality might be prevented by earlier diagnosis of HIV followed by timely initiation of ART.Keywords
This publication has 48 references indexed in Scilit:
- Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical areaHIV Medicine, 2007
- Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patientsCMAJ : Canadian Medical Association Journal, 2005
- Newly diagnosed HIV infections: review in UK and IrelandBMJ, 2005
- Trends in AIDS-Defining and Non--AIDS-Defining Malignancies among HIV-Infected Patients: 1989-2002Clinical Infectious Diseases, 2004
- Mortality in relation to smoking: 50 years' observations on male British doctorsBMJ, 2004
- Mortality and educational level among diabetic and non-diabetic population in the Turin Longitudinal Study: a 9-year follow-upInternational Journal of Epidemiology, 2004
- Trends in young adult mortality in three European cities: Barcelona, Bologna and Munich, 1986-1995Journal of Epidemiology and Community Health, 2001
- The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997AIDS, 1999
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998